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Dear Editor
The coronavirus disease 2019 (COVID-19) was first 
emerged from Wuhan, China, in late 2019, and has 
since been spreading progressively all around the world. 
Its prevalence is climbing increasingly and almost all 
countries worldwide are confronting this pandemic. As of 
April 11, 2020, reports obtained about the management of 
COVID-19 patients indicate that the mortality rate of the 
disease is around 5% with consideration of the active cases 
and 21% of the closed cases (1).
Preliminary experiences had indicated that the leading 
cause of death in COVID-19 patients was severe hypoxia 
following acute respiratory distress syndrome (2, 3); 
however, the gradually increasing information regarding 
the pathophysiology of the disease has shown that 
angiotensin-converting enzyme 2 (ACE2) is a cellular 
receptor for the severe acute respiratory syndrome-
coronavirus 2 (SARS-CoV-2) (4). The distribution of 
ACE2 receptor is widespread in the human body and is 
found in abundance in various tissue cells, including 
epithelial cells, vascular endothelial cells, kidney cells, 
brain tissue cells and etc. (5). Therefore, it is hypothesized 
that ARDS may not be the only cause of death in 
patients. Furthermore, recent findings demonstrating the 
inconsistency between the clinical manifestations of some 
patients with their imaging and laboratory findings has 
reinforced the mentioned hypothesis (3, 6). For instance, 
Zhou et al reported that 18% of non-severe cases and 3% 
of severe cases of COVID-19 had normal presentations in 
their chest radiography and computed tomography (CT) 
scans (7).
The existing literature regarding COVID-19 indicates 
that coagulopathy is a common disorder among these 
patients and is significantly related to the mortality rate 
and severity of the disease. The presence of ACE2 in 
blood vessels causes the vascular endothelial cells to be 
a convenient host for SARS-CoV-2. As a result, recent 
studies have reported numerous vascular thromboses 
occurring in various tissues such as lungs, brain and 
heart of COVID-19 patients. For example, a study on 184 
proved COVID-19 cases admitted to ICU indicated a 31% 
prevalence of vascular thrombosis among the patients. 
Between different kinds of thrombosis, pulmonary 
embolism was the most prevalent (81%) (8). Furthermore, 
a cohort study conducted on 183 patients demonstrated a 
relation between coagulopathy and poor prognosis among 
COVID-19 patients (9). Also, a case control study reported 
that anticoagulant treatment can reduce 28-day mortality 
rate in patients with sepsis induced coagulopathy (10). 
Such research findings indicate that coagulopathies are 
of utmost importance in COVID-19 patients. Hence, the 
present study aims to provide an anticoagulant treatment 
protocol which can be used in COVID-19 patients 
suspected or at risk of having thrombosis. 
The first step in the mentioned protocol is identifying 
the COVID-19 patients at risk of thromboembolism. 
Therefore, in this step, risk factors for thromboembolism 
in the patients should be monitored. These risk factors 
include inherited coagulation disorders, immobilization, 
pregnancy, contraceptive consuming, obesity and 
overweight, smoking, cardiovascular disorders, 
inflammatory bowel disease, family history of thrombosis, 
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recent history of thrombosis or pulmonary embolism, 
old age, cancer, recent trauma, recent surgery and etc. 
Presence of the mentioned risk factors can cause a 
COVID-19 patient to be at risk of coagulopathy.
The second step is to identify symptoms indicating 
of thrombosis. Symptoms which demonstrate an 
underlying thrombosis are divided into four main 
groups: (a) The primary and most important symptoms 
of thrombosis in COVID-19 patients are related to 
pulmonary embolism, since based on the reports, 81% of 
the thromboses are occurred in the lungs of COVID-19 
patients (8). Symptoms related to pulmonary embolism 
include dyspnea which cannot be justified by the extent 
of pulmonary involvement as observed in CT scan, 
decreased arterial oxygen saturation levels down to less 
than 85%, decreased oxygen saturation levels despite 
treatment and improvement of findings in chest CT 
scans, haemoptysis, pleuritic chest pain and the presence 
of findings in electrocardiography (ECG) indicating 
pulmonary embolism (S1Q3T3). (b) Symptoms related 
to stroke should also be taken into consideration. These 
symptoms include decreased level of consciousness which 
cannot be justified by the level of oxygen saturation and 
general hypoxemia, delirium, sudden speech impediment, 
decreased motor ability, impaired vision, inability to walk, 
confusion, imbalance, and sudden severe headache. (c) 
Symptoms related to cardiac ischemia are also of great 
importance. These symptoms include severe chest pain, 
changes in the EEG raising doubt over cardiac ischemia, 
increased levels of cardiac enzymes such as Troponin I. 
(d) Finally, symptoms related to deep thrombosis, such 
as pain in the limbs, redness, warmth of the limbs to the 
touch, worsening of the leg pain with bending of the foot, 
muscle crumps in the limbs and screen discoloration.
The third step includes monitoring of d-dimer levels. The 
d-dimer test should be a routine evaluation in COVID-19 
patients. There is no consensus on the optimum cut-off 
for d-dimer in COVID-19 patients. Studies on COVID-19 
have proposed a wide range cut offs for d-dimer (from 
1500 ng/mL to 5300 ng/mL) (11-13). In designing the 
present protocol, based on expert opinion a d-dimer 
of 1000 ng/mL was used. This cut-off can be modified 
based on the local clinical experience in other countries. 
If d-dimer levels are less than 1000 ng/mL, low molecular 
weight heparin (LMWH) should be given as a prophylaxis 
at a daily dose of 40 mg. Also, if d-dimer levels are above 
Figure 1. Recommended flowchart for the prevention and treatment of COVID-19 suspected thromboembolism patients. CT: Chest computed 
tomography scan without contrast; LMWH: Low molecular weight heparin; PTE: pulmonary thromboembolism; ULN: Upper limit of normal.
Safari and Yousefifard
Journal of Emergency Practice and Trauma, 2021, 7(1), 4-66
1000 ng/mL, further evaluations are recommended. 
In cases of any coagulation disorders observed in the blood 
test, PaO2≤60%, imaging evidences of thromboembolism, 
right ventricular dysfunction in echocardiography or 
ECG changes, and CT angiography of the lungs are 
recommended, and if the pulmonary artery thrombosis 
is confirmed, LMWH 80 mg/daily should be prescribed 
for the patients. Clearly, in cases of suspected thrombotic 
related disorders in brain and heart, diagnostic procedures 
such as MRI and coronary angiography are recommended. 
If vascular thromboses are ruled out, prophylaxis 
treatment (LMWH 40 mg/daily) is recommended for the 
patients. 
As we said previously, 81% of thrombotic events in 
COVID-19 patients are related to pulmonary embolism. 
Therefore, the proposed protocol is a recommendation for 
the management of patients suspected or at risk of having 
pulmonary thromboembolism as the most frequent 
thrombotic event in COVID-19 cases (Figure 1).
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